Literature DB >> 16185372

Metered-dose inhalers and dry powder inhalers in aerosol therapy.

Dean R Hess1.   

Abstract

Inhaled drug delivery is an important part of the armamentarium of clinicians caring for patients with pulmonary disease. An increasing variety of metered-dose inhalers and dry powder inhalers are becoming available. This has been driven by the development of new formulations and the impending ban on chlorofluorocarbon propellants. The result is a proliferation of devices, resulting in a confusing number of choices for the clinician, as well as confusion for patients trying to use these devices correctly. The presenters at this conference included many of the world's authorities on metered-dose inhalers and dry powder inhalers, and were an appropriate mix of academic aerosol scientists, clinician researchers with an interest in aerosol therapy, and aerosol scientists working for industry. Improper inhaler technique is common among patients. One of the important take-home messages of this conference is the importance of clinicians knowledgeable in the use of aerosol delivery devices and clinicians' ability to teach patients how to use these devices correctly. Respiratory therapists are uniquely positioned to provide this service, and there is evidence that respiratory therapists may do this better than others. The proceedings of this conference provide the current state of the art of metered-dose inhalers and dry powder inhalers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16185372

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  2 in total

1.  Efficacy and safety of the single-capsule combination of fluticasone/formoterol in patients with persistent asthma: a non-inferiority trial.

Authors:  Marti Antilla; Fábio Castro; Álvaro Cruz; Adalberto Rubin; Nelson Rosário; Rafael Stelmach
Journal:  J Bras Pneumol       Date:  2014 Nov-Dec       Impact factor: 2.624

Review 2.  Considerations for managing chronic obstructive pulmonary disease in the elderly.

Authors:  George E Taffet; James F Donohue; Pablo R Altman
Journal:  Clin Interv Aging       Date:  2013-12-13       Impact factor: 4.458

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.